Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Core Insights - Immunovant reported its financial results for the third quarter ended December 31, 2025, highlighting significant developments in its clinical trials and financial position [1] Recent Highlights and Upcoming Milestones - The trial for IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) is fully enrolled, with topline data expected in the second half of 2026 [2][9] - Other clinical developments for IMVT-1402 are on track, including trials in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), and Sjögren's disease (SjD) [2][9] - A financing round in December 2025 raised approximately $550 million, extending the company's cash runway to support the potential launch of IMVT-1402 in GD [2][9] Financial Highlights for Fiscal Third Quarter - As of December 31, 2025, cash and cash equivalents totaled $994.5 million, providing sufficient funds for ongoing clinical trials [4] - Research and development (R&D) expenses were $98.9 million for the quarter, up from $94.5 million in the same period of 2024, primarily due to clinical trial activities for IMVT-1402 [5] - General and administrative (G&A) expenses decreased to $15.4 million from $19.8 million year-over-year, attributed to lower personnel and market research costs [6] Net Loss - The net loss for the third quarter was $110.6 million ($0.61 per share), slightly down from $111.1 million ($0.76 per share) in the prior year [8] - Non-GAAP net loss was $97.5 million for the quarter, compared to $99.5 million in the same quarter of 2024 [8] Financial Highlights for Fiscal Nine Months - For the nine months ended December 31, 2025, R&D expenses totaled $314.4 million, an increase from $267.3 million in the same period of 2024 [11] - G&A expenses for the nine months were $59.0 million, up from $57.1 million year-over-year [13] - The net loss for the nine months was $357.8 million ($2.04 per share), compared to $307.4 million ($2.10 per share) in the previous year [15]